Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 7/20 | 0.36 |
| ▸ | CES1 | P23141 | 5/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23825006 | 1.00 | MAPT (0.44) | MAPTFDPSLMNAFAAHCES1 | |
| SCHEMBL3010559 | 0.98 | MAPT (0.41) | MAPTFDPSLMNAFAAHCES1 | |
| SCHEMBL2998995 | 0.91 | FDPS (0.34) | MAPTFDPSFAAHCES1CES2 | |
| SCHEMBL9444837 | 0.88 | MAPT (0.41) | MAPTFDPSLMNAFAAHCES1 | |
| SCHEMBL23825142 | 0.88 | MAPT (0.44) | MAPTFDPSLMNAFAAHCES1 | |
| SCHEMBL23825055 | 0.88 | MAPT (0.44) | MAPTFDPSLMNAFAAHCES1 | |
| SCHEMBL23825039 | 0.88 | MAPT (0.44) | MAPTFDPSLMNAFAAHCES1 | |
| SCHEMBL23825196 | 0.88 | MAPT (0.44) | MAPTFDPSLMNAFAAHCES1 | |
| SCHEMBL23825146 | 0.86 | MAPT (0.38) | MAPTFDPSLMNAFAAHCES1 | |
| SCHEMBL23825044 | 0.85 | MAPT (0.41) | MAPTFDPSLMNAFAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3882235-B1 | PRODUCTION METHOD FOR ISOCYANATE COMPOUND | UNIV KOBE NAT UNIV CORP (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-12060312-B2 | Production method for isocyanate compound | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2024-08-13 | — | — | US | disclosed |
| WO-2022065133-A1 | METHOD FOR PRODUCING CARBONATE COMPOUND | 国立大学法人神戸大学 | 2022-03-31 | — | — | WO | disclosed |
| US-20220002234-A1 | PRODUCTION METHOD FOR ISOCYANATE COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2022-01-06 | — | — | US | disclosed |
| EP-3882235-A1 | PRODUCTION METHOD FOR ISOCYANATE COMPOUND | National University Corporation Kobe University (JP) | 2021-09-22 | — | — | EP | disclosed |
| CN-113015719-A | Method for producing isocyanate compound | 国立大学法人神户大学 | 2021-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060312-B2 | Production method for isocyanate compound | IDH2, CBR3, IDH3A | MAPT 1751/4885FDPS 216/4885LMNA 3593/4885 |
| US-20220002234-A1 | PRODUCTION METHOD FOR ISOCYANATE COMPOUND | IDH2, CBR3, IDH3A | MAPT 1751/4885FDPS 216/4885LMNA 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.